Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa

Pharmacogenetics

Volumn 14, Issue 10, 2004, Pages 691-700

  Wojnowski, Leszek ^a,f   Turner, Paul C ^b   Pedersen, Bonnie ^c   Hustert, Elisabeth ^d   Brockmöller, Jürgen ^f   Mendy, Maimuna ^e   Whittle, Hilton C ^e   Kirk, Greg ^c   Wild, Christopher P ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Epidauros Biotechnologie AG   (Germany)

^e MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Aflatoxins; CYP3A5; Genetic polymorphism; Hepatocellular carcinoma

Indexed keywords

AFLATOXIN; AFLATOXIN B1; ALBUMIN; BIOLOGICAL MARKER; CYTOCHROME P450 3A5; GLUTATHIONE;

AFRICAN AMERICAN; ALLELE; ARTICLE; CANCER RISK; CATALYSIS; DATA ANALYSIS; DNA ADDUCT; EXPOSURE; GAMBIA; GENE LOCATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HAPLOTYPE; HEPATITIS VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MUTAGENICITY; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AFLATOXIN B1; AFLATOXINS; AGED; ALBUMINS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; DNA; FEMALE; GAMBIA; GENE EXPRESSION; GENE FREQUENCY; HAPLOTYPES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTAGENS; POLYMORPHISM, GENETIC; RISK FACTORS; VARIATION (GENETICS);

EID: 6944246168     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200410000-00007     Document Type: Article

References (23)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37:S4-S66.
2. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002; 17(6):471-481.
3. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000; 462:381-393.
4. Henry SH, Bosch FX, Troxell TC, Bolger PM. Policy forum: public health. Reducing liver cancer-global control of aflatoxin. Science 1999; 286(5449):2453-2454.
5. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langouet S. Activation and detoxication of aflatoxin B1. Mutat Res 186-1998; 402(1-2):121-128.
6. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, et al. Expression of cytochrome p450 3a5 in escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities [published erratum appears in Arch Biochem Biophys 1995; 318(2):498]. Arch Biochem Biophys 1995; 317(2):374-384.
7. Gillam EM, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PE, et al. Expression of cytochrome p450 3a5 in escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities [published erratum appears in Arch Biochem Biophys 1995; 318(2):498]. Arch Biochem Biophys 1995; 317(2):374-384.
8. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, et al. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochem (Mosc) 1998; 37(36):12536-12545.
9. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
10. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11(9):773-779.
11. Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int J Cancer 2000; 86:1-7.
12. Rohde K, Fuerst R. Haplotyping and estimation of haplotype frequencies for closely linked biallelic multilocus genetic phenotypes including nuclear family information. Hum Mutat 2001; 17(4):289-295.
13. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13(8):461-472.
14. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 2003; 38(4):978-988.
15. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 2003; 31(6):755-761.
16. Kelly EJ, Erickson KE, Sengstag C, Eaton DL. Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in aflatoxin B-1 detoxification. Toxicol Sci 2002; 65(1):35-42.
17. Johnson WW, Yamazaki H, Shimada T, Ueng, YF, Guengerich FP. Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Chem Res Toxicol 1997; 10(6):672-676.
18. Chemin I, Takahashi S, Belloc C, Lang MA, Ando K, Guidotti LG, et al . Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant-hepatitis. Hepatology 1996; 24(3):649-656.
19. Chemin I, Ohgaki H, Chisari FV, Wild CP. Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver 1999; 19:81-87.
20. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 1994; 11:74-80.
21. Schuetz JD, Schuetz EG, Thottassery JV, Guzelian PS, Strom S, Sun D. Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol Pharmacol 1996; 49(1):63-72.
22. Hukkanen J, Vaisanen T, Lassila A, Piipari R, Anttila S, Pelkonen O, et al. Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther 2003; 304(2):745-752.
23. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299(3):849-857.